ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Glass Lewis recommands stock consolidation

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Nov 02, 2021 10:31am

118 Views

Post# 34076953

RE:Glass Lewis recommands stock consolidation

I really like this part of the article, meaning this will be a long term stock to hold. Very excited!

Glass Lewis is a leading independent, third party proxy advisory firm who, among other services, provide proxy-voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs